NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGV
Post# of 50
(Total Views: 126)
Posted On: 01/29/2024 3:06:27 PM
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has received notice from the United States Patent and Trademark Office (“USPTO”) of patent allowance for Medicinal Signaling Cells (“MSCs”). The patent covers the technology behind LGVN’s lead investigational product Lomecel-B(TM) and will impact patients with Aging-related Frailty receiving vaccines for conditions such as COVID-19 and the flu. Lomecel-B is a living-cell product made from MSCs that are essential to the body’s endogenous biological repair mechanism and that have been shown to perform complex functions in the body, including the formation of new tissue. The patent covers the impact of Lomecel-B on favorable modulation of the immune system, which is a foundational mechanism of action of the product. Longeveron is currently conducting trials in Aging-Related Frailty and Alzheimer’s disease as well a phase 2 trial for Hypoplastic Left Heart Syndrome (“HLHS”), a rare and often fatal cardiac condition in newborn infants. “These newly allowed claims extend our patent estate to include the use of Lomecel-B in conjunction with or after patients receive vaccines to enhance vaccine immune response,” said Longeveron cofounder, chief scientific officer and chair Joshua M. Hare, MD, FACC, FAHA, in the press release. “We believe this use for Lomecel-B and the broader potential it holds for patients in our current Aging-Related Frailty and Alzheimer’s disease trials reflects the broader potential of Lomecel-B.”
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://nnw.fm/LGVN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has received notice from the United States Patent and Trademark Office (“USPTO”) of patent allowance for Medicinal Signaling Cells (“MSCs”). The patent covers the technology behind LGVN’s lead investigational product Lomecel-B(TM) and will impact patients with Aging-related Frailty receiving vaccines for conditions such as COVID-19 and the flu. Lomecel-B is a living-cell product made from MSCs that are essential to the body’s endogenous biological repair mechanism and that have been shown to perform complex functions in the body, including the formation of new tissue. The patent covers the impact of Lomecel-B on favorable modulation of the immune system, which is a foundational mechanism of action of the product. Longeveron is currently conducting trials in Aging-Related Frailty and Alzheimer’s disease as well a phase 2 trial for Hypoplastic Left Heart Syndrome (“HLHS”), a rare and often fatal cardiac condition in newborn infants. “These newly allowed claims extend our patent estate to include the use of Lomecel-B in conjunction with or after patients receive vaccines to enhance vaccine immune response,” said Longeveron cofounder, chief scientific officer and chair Joshua M. Hare, MD, FACC, FAHA, in the press release. “We believe this use for Lomecel-B and the broader potential it holds for patients in our current Aging-Related Frailty and Alzheimer’s disease trials reflects the broader potential of Lomecel-B.”
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://nnw.fm/LGVN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Longeveron Inc. (LGVN) Stock Research Links
Scroll down for more posts ▼